FDA Approves First Biosimilar to Non-Hodgkin ' s Lymphoma Drug

WEDNESDAY, Nov. 28, 2018 -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin ' s lymphoma drug Rituxan, the agency said today. Truxima, as with Rituxan, is approved to treat...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news